Search

Your search keyword '"Maestro-de la Calle, Guillermo"' showing total 3 results
Start Over Author "Maestro-de la Calle, Guillermo" Publisher bmj publishing group
3 results on '"Maestro-de la Calle, Guillermo"'

1. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study

Author

Albasanz-Puig, Adaia, Gudiol, Carlota, Parody, Rocio, Tebe, Cristian, Akova, Murat, Araos, Rafael, Bote, Anna, Brunel, Anne-Sophie, Calik, Sebnem, Drgona, Lubos, Garcia, Estefania, Hemmati, Philipp, Herrera, Fabian, Ibrahim, Karim Yaqub, Isler, Burcu, Kanj, Souha, Kern, Winfried, Maestro de la Calle, Guillermo, Manzur, Adriana, Ivan Marin, Jorge, Marquez-Gomez, Ignacio, Martin-Davila, Pilar, Mikulska, Malgorzata, Montejo, Jose Miguel, Montero, Milagros, Paz Morales, Hugo Manuel, Morales, Isabel, Novo, Andres, Oltolini, Chiara, Peghin, Maddalena, Luis del Pozo, Jose, Puerta-Alcalde, Pedro, Ruiz-Camps, Isabel, Resat Sipahi, Oguz, Tilley, Robert, Yanez, Lucrecia, Ribeiro Gomes, Marisa Zenaide, Carratala, Jordi, Cuervo, Guillermo, Escrihuela-Vidal, Francesc, Tubau, Fe, Rodriguez Arias, Marisol, Merve Ayaz, Caglayan, Munita, Jose, Gasch, Oriol, Capilla, Silvia, Bochud, Pierre-Yves, Manuel, Oriol, Torre-Cisneros, Julian, Tabares, Salvador, Serrano Lopez, Josefina, Maschmeyer, Georg, Torres, Diego, Abdala, Edson, Bittencourt, Driele Peixoto, El Zein, Saeed, Jabbour, Jean-Francois, Bertz, Hartmut, Peyerl-Hoffmann, Gabriele, Lizasoain, Manuel, Maria Aguado, Jose, Clemencia Correa, Lina, Palop, Begona, Fortun, Jesus, Magnasco, Laura, Cespedes, Roberto, Lopez-Soria, Leire, Pablo Horcajada, Juan, Montaguti, Mia Hold, de Cueto, Marina, Rodriguez-Bano, Jesus, Greco, Raffaella, Cichero, Paola, Bassetti, Matteo, Castaldo, Nadia, Sangro del Alcazar, Paloma, Cardozo, Celia, Garcia-Vidal, Carolina, Aguilar-Company, Juan, Larrosa, Nieves, Uyan-Onal, Ayse, Nazli-Zeka, Arzu, Vasconcelos de Freitas, Wania, da Silva Machado, Amanda Aparecida, IRONIC Study Grp, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), European Commission, IRONIC study group, Cuervo, G., Escrihuela-Vidal, F., Arias, M.R., Ayaz, C.M., Munita, J., Gasch, O., Bochud, P.Y., Manuel, O., Torres, D., Zein, S.E., Jabbour, J.F., Bertz, H., Peyerl-Hoffmann, G., Lizasoain, M., Aguado, J.M., Palop, B., Fortún, J., Maschmeyer, G., Magnasco, L., Céspedes, R., López-Soria, L., Horcajada, J.P., Montaguti, M.H., Cueto, M., Rodríguez-Baño, J., Greco, R., Cichero, P., Bassetti, M., Castaldo, N., Del Alcázar, P.S., Cardozo, C., Garcia-Vidal, C., Aguilar-Company, J., Larrosa, N., Uyan-Onal, A., Nazli-Zeka, A., Eylul, D., Turkey, I., Clemencia Correa, L., de Freitas, W.V., da Silva Machado, A.A., Institut Català de la Salut, [Albasanz-Puig A, Gudiol C] Departament de Malalties Infeccioses, Hospital Universitari de Bellvitge, Barcelona, Spain. Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. Universitat de Barcelona, Barcelona, Spain. Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Madrid, Spain. [Parody R] Departament d’hematologia, Institut Català d' Oncologia (ICO) Barcelona, Spain. Hospital Duran i Reynals, Barcelona, Spain. . Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. [Tebe C] Servei d’estadística, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. Universitat Rovira i Virgili, Barcelona, Spain. [Akova M] Infectious Diseases Department, Hacettepe University School of Medicine, Ankara, Turkey. [Araos R] Infectious Diseases Department, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana, Universidad del Desarrollo, Santiago de Chile, Chile. [Ruiz-Camps I] Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, and Ege Üniversitesi

Subjects
Microbiological Phenomena::Drug Resistance, Microbial [PHENOMENA AND PROCESSES], Research design, infecciones bacterianas y micosis::infecciones bacterianas y micosis::infección::sepsis::bacteriemia [ENFERMEDADES], bacteraemia, Time Factors, modelos logísticos, International Cooperation, humanos, resistencia a medicamentos, Drug Resistance, Bacteremia, Bacteria::bacterias gramnegativas::bacterias aerobias gramnegativas::bacilos y cocos aerobios gramnegativos::Pseudomonadaceae::Pseudomonas::Pseudomonas aeruginosa [ORGANISMOS], bloodstream infection, multidrug-resistant, neutropenia, onco-haematological patients, pseudomonas aeruginosa, estudios multicéntricos como asunto, Bacterièmia, 0302 clinical medicine, Bacteria::Gram-Negative Bacteria::Gram-Negative Aerobic Bacteria::Gram-Negative Aerobic Rods and Cocci::Pseudomonadaceae::Pseudomonas::Pseudomonas aeruginosa [ORGANISMS], Drug Resistance, Multiple, Bacterial, Neoplasms, Clinical endpoint, Onco-haematological patients, Multicenter Studies as Topic, Multidrug-resistant, Microorganismes - Resistència als medicaments, Otros calificadores::Otros calificadores::/inmunología [Otros calificadores], 030212 general & internal medicine, neoplasias, 0303 health sciences, Neutropènia, fenómenos microbiológicos::farmacorresistencia microbiana [FENÓMENOS Y PROCESOS], Incidence (epidemiology), bacteriemia, General Medicine, Bacterial Infections and Mycoses::Bacterial Infections and Mycoses::Infection::Sepsis::Bacteremia [DISEASES], Anti-Bacterial Agents, Malalts de càncer, Observational Studies as Topic, Research Design, Pseudomonas aeruginosa, Ceftolozane, antibacterianos, medicine.drug, medicine.medical_specialty, Tazobactam, Neutropenia, Pseudomones aeruginosa, Bloodstream infection, 03 medical and health sciences, factores de tiempo, Other subheadings::Other subheadings::/immunology [Other subheadings], Internal medicine, Pseudomonas, medicine, Humans, Pseudomonas Infections, Anti-Bacterial Agents/therapeutic use, Bacteremia/drug therapy, Bacteremia/mortality, Cephalosporins/therapeutic use, Logistic Models, Neoplasms/complications, Neutropenia/complications, Pseudomonas Infections/drug therapy, Pseudomonas aeruginosa/isolation & purification, Retrospective Studies, Tazobactam/therapeutic use, Resistència als medicaments, infecciones por Pseudomonas, cefalosporinas, 030306 microbiology, business.industry, estudios retrospectivos, enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos leucocitarios::leucopenia::agranulocitosis::neutropenia [ENFERMEDADES], cooperación internacional, Retrospective cohort study, Cancer patients, medicine.disease, Cephalosporins, Drug resistance, Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropenia [DISEASES], Bacteraemia, Observational study, business, diseño de la investigación
Abstract

The IRONIC study group: Cuervo, Guillermo; Escrihuela-Vidal, Francesc; Tubau, Fe; Rodriguez Arias, Marisol; Merve Ayaz, Caglayan; Munita, Jose; Gasch, Oriol; Capilla, Silvia; Bochud, Pierre-Yves; Manuel, Oriol; Torre-Cisneros, Julian; Tabares, Salvador; Serrano Lopez, Josefina; Maschmeyer, Georg; Torres, Diego; Abdala, Edson; Bittencourt, Driele Peixoto; El Zein, Saeed; Jabbour, Jean-Francois; Bertz, Hartmut; Peyerl-Hoffmann, Gabriele; Lizasoain, Manuel; Maria Aguado, Jose; Clemencia Correa, Lina; Palop, Begona; Fortun, Jesus; Magnasco, Laura; Cespedes, Roberto; Lopez-Soria, Leire; Pablo Horcajada, Juan; Montaguti, Mia Hold; de Cueto, Marina; Rodriguez-Bano, Jesus; Greco, Raffaella; Cichero, Paola; Bassetti, Matteo; Castaldo, Nadia; Sangro del Alcazar, Paloma; Cardozo, Celia; Garcia-Vidal, Carolina; Aguilar-Company, Juan; Larrosa, Nieves; Uyan-Onal, Ayse; Nazli-Zeka, Arzu; Vasconcelos de Freitas, Wania; da Silva Machado, Amanda Aparecida, [Introduction]: Pseudomonas aeruginosa (PA) has historically been one of the major causes of severe sepsis and death among neutropenic cancer patients. There has been a recent increase of multidrug-resistant PA (MDRPA) isolates that may determine a worse prognosis, particularly in immunosuppressed patients. The aim of this study is to establish the impact of antibiotic resistance on the outcome of neutropenic onco-haematological patients with PA bacteraemia, and to identify the risk factors for MDRPA bacteraemia and mortality., [Methods and analysis]: This is a retrospective, observational, multicentre, international study. All episodes of PA bacteraemia occurring in neutropenic oncohaematological patients followed up at the participating centres from 1 January 2006 to 31 May 2018 will be retrospectively reviewed. The primary end point will be overall case-fatality rate within 30 days of onset of PA bacteraemia. The secondary end points will be to describe the following: the incidence and risk factors for multidrugresistant and extremely drug-resistant PA bacteraemia (by comparing the episodes due to susceptible PA with those produced by MDRPA), the efficacy of ceftolozane/tazobactam, the rates of persistent bacteraemia and bacteraemia relapse and the risk factors for very early (48 hours), early (7 days) and overall (30 days) case-fatality rates., [Ethics and dissemination]: The Clinical Research Ethics Committee of Bellvitge University Hospital approved the protocol of the study at the primary site. To protect personal privacy, identifying information of each patient in the electronic database will be encrypted. The processing of the patients’ personal data collected in the study will comply with the Spanish Data Protection Act of 1998 and with the European Directive on the privacy of data. All data collected, stored and processed will be anonymised. Results will be reported at conferences and in peerreviewed publications., This study was supported by Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001) and co-financed by European Development Regional Fund “A way to achieve Europe”, Operative Programme Intelligent Growth 2014‐2020.

Published
2019

2. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study

Author

Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), European Commission, Albasanz-Puig, Adaia, Gudiol, Carlota, Parody, Rocío, Tebé, Cristian, Akova, Murat, Araos, Rafael, Bote, Anna, Brunel, Anne-Sophie, Calik, Sebnem, Drgona, Lubos, García, Estefanía, Hemmati, Philipp, Herrera, Fabián, Yaqub Ibrahim, Karim, Isler, Burcu, Kanj, Souha S., Kern, Winfried, Maestro-de la Calle, Guillermo, Manzur, Adriana, Marin, Jorge Iván, Márquez-Gómez, Ignacio, Martín-Dávila, Pilar, Mikulska, Malgorzata, Montejo, Miguel, Montero, Milagros, Paz Morales, Hugo Manuel, Morales, Isabel, Novo, Andrés, Oltolini, Chiara, Peghin, Maddalena, Pozo, José Luis del, Puerta-Alcalde, Pedro, Ruiz-Camps, Isabel, Sipahi, Oguz Resat, Tilley, Robert, Yáñez, Lucrecia, Gomes, Marisa Z. R., Carratalà, Jordi, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), European Commission, Albasanz-Puig, Adaia, Gudiol, Carlota, Parody, Rocío, Tebé, Cristian, Akova, Murat, Araos, Rafael, Bote, Anna, Brunel, Anne-Sophie, Calik, Sebnem, Drgona, Lubos, García, Estefanía, Hemmati, Philipp, Herrera, Fabián, Yaqub Ibrahim, Karim, Isler, Burcu, Kanj, Souha S., Kern, Winfried, Maestro-de la Calle, Guillermo, Manzur, Adriana, Marin, Jorge Iván, Márquez-Gómez, Ignacio, Martín-Dávila, Pilar, Mikulska, Malgorzata, Montejo, Miguel, Montero, Milagros, Paz Morales, Hugo Manuel, Morales, Isabel, Novo, Andrés, Oltolini, Chiara, Peghin, Maddalena, Pozo, José Luis del, Puerta-Alcalde, Pedro, Ruiz-Camps, Isabel, Sipahi, Oguz Resat, Tilley, Robert, Yáñez, Lucrecia, Gomes, Marisa Z. R., and Carratalà, Jordi

Abstract

[Introduction]: Pseudomonas aeruginosa (PA) has historically been one of the major causes of severe sepsis and death among neutropenic cancer patients. There has been a recent increase of multidrug-resistant PA (MDRPA) isolates that may determine a worse prognosis, particularly in immunosuppressed patients. The aim of this study is to establish the impact of antibiotic resistance on the outcome of neutropenic onco-haematological patients with PA bacteraemia, and to identify the risk factors for MDRPA bacteraemia and mortality., [Methods and analysis]: This is a retrospective, observational, multicentre, international study. All episodes of PA bacteraemia occurring in neutropenic oncohaematological patients followed up at the participating centres from 1 January 2006 to 31 May 2018 will be retrospectively reviewed. The primary end point will be overall case-fatality rate within 30 days of onset of PA bacteraemia. The secondary end points will be to describe the following: the incidence and risk factors for multidrugresistant and extremely drug-resistant PA bacteraemia (by comparing the episodes due to susceptible PA with those produced by MDRPA), the efficacy of ceftolozane/tazobactam, the rates of persistent bacteraemia and bacteraemia relapse and the risk factors for very early (48 hours), early (7 days) and overall (30 days) case-fatality rates., [Ethics and dissemination]: The Clinical Research Ethics Committee of Bellvitge University Hospital approved the protocol of the study at the primary site. To protect personal privacy, identifying information of each patient in the electronic database will be encrypted. The processing of the patients’ personal data collected in the study will comply with the Spanish Data Protection Act of 1998 and with the European Directive on the privacy of data. All data collected, stored and processed will be anonymised. Results will be reported at conferences and in peerreviewed publications.

Published
2019

3. Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR)

Author

Gudiol, Carlota, Royo-Cebrecos, Cristina, Tebé, Cristian, Abdala, Edson, Akova, Murat, Álvarez-Marín, Rocío, Maestro-de la Calle, Guillermo, Cano, Ángela, Cervera, Carlos, Clemente, Wanessa T., Martín-Dávila, Pilar, Freifeld, Alison, Gómez, Lucía, Gottlieb, Thomas, Gurguí, Mercè, Herrera, Fabián, Manzur, Adriana, Maschmeyer, Georg, Meije, Yolanda, Montejo, Miguel, Peghin, Maddalena, Rodríguez-Baño, Jesús, Ruiz-Camps, Isabel, Sukiennik, Teresa C., Carratalà, Jordi, BICAR study group., [Gudiol,C, Royo-Cebrecos,C, Carratalà,J] Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. [Gudiol,C] Duran i Reynals Hospital, ICO, L'Hospitalet de Llobregat, Barcelona, Spain. [Gudiol,C, Cano,A, Meije,Y, Montejo,M, Rodríguez-Baño,J, Ruiz-Camps,I, Carratalà,J] REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain. [Tebe,C] Statistics Advisory Service, Institute of Biomedical Research of Bellvitge, Rovira i Virgili University, L'Hospitalet de Llobregat, Barcelona, Spain. [Abdala,E] Faculty of Medicine, Instituto do Câncer do Estado de São Paulo, University of São Paulo, Sao Paulo, Brazil. [Akova,M] Hacettepe University School of Medicine, Ankara, Turkey. [Álvarez,R] Infectious Diseases Research Group, Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), University of Seville/CSIC/University Hospitals Virgen del Rocio and Virgen Macarena, Seville, Spain. [Maestro-de la Calle,G] Infectious Diseases Unit, Instituto de Investigación Hospital '12 de Octubre' (i+12), '12 de Octubre' University Hospital, School of Medicine, Universidad Complutense, Madrid, Spain. [Cano,A] Reina Sofía University Hospital-IMIBIC-UCO, Córdoba, Spain. [Cervera,C] University Hospital of Alberta, Edmonton, Alberta, Canada. [Clemente,WT] Infectious Disease Consultant, Digestive Transplant Service, Hospital das Clínicas, Universidade Federal Minas Gerais, Brazil. [Martín-Dávila,P] Infectious Diseases Department, Ramon y Cajal Hospital, Madrid, Spain. [Freifeld,A] Infectious Diseases Section, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA. [Gómez,L] Department of Internal Medicine, University Hospital Mútua de Terrassa, Barcelona, Spain. [Gottlieb,T] Department of Microbiology & Infectious Diseases, Concord Hospital, Concord, New South Wales, Australia. [Gurguí,M] Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau and Instituto de Investigación Biomédica Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. [Herrera,F] Infectious Diseases Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina. [Manzur,A] Infectious Diseases, Hospital Rawson, San Juan, Argentina. [Maschmeyer,G] Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Academic Teaching Hospital of Charité University Medical School, Berlin, Germany. [Meije,Y] Infectious Disease Unit, Internal Medicine Department, Barcelona Hospital, SCIAS, Barcelona, Spain. [Montejo,M] Infectious Diseases Unit, Cruces University Hospital, Bilbao, Spain. [Peghin,M] Infectious Diseases Division, Santa Maria Misericordia University Hospital, Udine, Italy. [Rodríguez-Baño,J] Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, University Hospitals Virgen Macarena and Virgen del Rocío-IBiS, Department of Medicine, University of Seville, Seville, Spain. [Ruiz-Camps,I] Infectious Diseases Department, Vall d'Hebrón University Hospital, Barcelona, Spain. [Sukiennik,TC] Hospital Santa Casa de Misericórdia de Porto Alegre, Brazil., This study was supported by Ministerio de Economía y Competitividad, Instituto de Salud Carlos III—co-financed by European Development Regional Fund ‘A way to achieve Europe’ ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015)., Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, European Commission, and Red Española de Investigación en Patología Infecciosa

Subjects
Humanities::Humanities::Ethics::Ethics Committees::Ethics Committees, Research [Medical Subject Headings], Male, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [Medical Subject Headings], Bacteremia, Comités de ética en investigación, Carbapenémicos, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], haematologic stem cell transplant, polycyclic compounds, Protocol, beta-lactam/beta-lactamase inhibitors, Diseases::Bacterial Infections and Mycoses::Infection::Sepsis [Medical Subject Headings], Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Amidohydrolases::beta-Lactamases [Medical Subject Headings], Diseases::Bacterial Infections and Mycoses::Bacterial Infections::Bacteremia [Medical Subject Headings], Enterobacteriaceae Infections, Hematopoietic Stem Cell Transplantation, Haematologic stem cell transplant, Middle Aged, Anti-Bacterial Agents, Infectious Diseases, Organisms [Medical Subject Headings], Beta-lactam/beta-lactamase inhibitors, Hematologic Neoplasms, Organisms::Bacteria::Gram-Negative Bacteria [Medical Subject Headings], Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropenia [Medical Subject Headings], Drug Therapy, Combination, Female, beta-Lactamase Inhibitors, Chemicals and Drugs::Organic Chemicals::Amides::Lactams::beta-Lactams::Carbapenems [Medical Subject Headings], Trasplante de células madre hematopoyéticas, Adult, Neutropenia, Adolescent, beta-Lactams, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Hematopoietic Stem Cell Mobilization [Medical Subject Headings], Health Care::Health Care Facilities, Manpower, and Services::Health Facilities::Hospital Units::Intensive Care Units [Medical Subject Headings], Chemicals and Drugs::Organic Chemicals::Amides::Lactams::beta-Lactams [Medical Subject Headings], Humans, Bacterias gramnegativas, Aged, Retrospective Studies, biochemical phenomena, metabolism, and nutrition, bacterial infections and mycoses, ESBLs, Superinfection, bacteria, Bacteraemia, Diseases::Bacterial Infections and Mycoses::Infection::Opportunistic Infections::Superinfection [Medical Subject Headings], human activities
Abstract

[Introduction] Bloodstream infection (BSI) due to extended-spectrum β-lactamase-producing Gram-negative bacilli (ESBL-GNB) is increasing at an alarming pace worldwide. Although β-lactam/β-lactamase inhibitor (BLBLI) combinations have been suggested as an alternative to carbapenems for the treatment of BSI due to these resistant organisms in the general population, their usefulness for the treatment of BSI due to ESBL-GNB in haematological patients with neutropaenia is yet to be elucidated. The aim of the BICAR study is to compare the efficacy of BLBLI combinations with that of carbapenems for the treatment of BSI due to an ESBL-GNB in this population., [Methods and analysis] A multinational, multicentre, observational retrospective study. Episodes of BSI due to ESBL-GNB occurring in haematological patients and haematopoietic stem cell transplant recipients with neutropaenia from 1 January 2006 to 31 March 2015 will be analysed. The primary end point will be case-fatality rate within 30 days of onset of BSI. The secondary end points will be 7-day and 14-day case-fatality rates, microbiological failure, colonisation/infection by resistant bacteria, superinfection, intensive care unit admission and development of adverse events., [Sample size] The number of expected episodes of BSI due to ESBL-GNB in the participant centres will be 260 with a ratio of control to experimental participants of 2., [Ethics and dissemination] The protocol of the study was approved at the first site by the Research Ethics Committee (REC) of Hospital Universitari de Bellvitge. Approval will be also sought from all relevant RECs. Any formal presentation or publication of data from this study will be considered as a joint publication by the participating investigators and will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE). The study has been endorsed by the European Study Group for Bloodstream Infection and Sepsis (ESGBIS) and the European Study Group for Infections in Compromised Hosts (ESGICH)., This study was supported by Ministerio de Economía y Competitividad, Instituto de Salud Carlos III—co-financed by European Development Regional Fund ‘A way to achieve Europe’ ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015).

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results